HeatBiologicsvaccine

2020年12月16日 — The company's gp96 platform is designed to activate immune responses against cancer or pathogenic antigens. The Company has multiple product ...

2021年5月5日 — ... vaccine, today provided financial, clinical and operational updates for the first quarter ended March 31, 2021. Jeff Wolf, Chief Executive ...

2020年9月2日 — A collaborative initiative to develop a COVID-19 vaccine has demonstrated positive results in a preclinical study, according to researchers ...

2020年8月3日 — Heat's vaccine will use a genetically engineered combination of a common protein already found in human cells called gp96, along with viral ...

Heat Biologics has licensed patents from the University of Miami that it will use to develop vaccines against the Zika virus. The Zika program will be ...

2021年11月30日 — RapidVax is designed as a rapid programmable vaccine to target a comprehensive range of emerging biological threats. Heat is showcasing a poster ...

2020年9月1日 — One effort to develop a SARS-CoV-2 vaccine focuses on combining antibody and T cell immunity, using a gp96 protein based technology.

由 L Padula 著作 · 2022 · 被引用 1 次 — Our allogeneic cellular vaccine, based on a secreted form of the heat-shock protein gp96-Ig, achieves high frequencies of polyclonal CD8 + T cell responses to ...

2020年8月3日 — Waisman Biomanufacturing at the University of Wisconsin–Madison is partnering with Heat Biologics to produce a COVID-19 vaccine for phase 1 and